



Clemens received his medical degree from the University of Vienna, Austria. He then trained and researched at the Clinical Pharmacology and Dermatology Departments of the Medical University of Vienna and obtained a specialist degree in Dermatology with a focus on dermato-oncology. Following a move to the US with his family, he spent several years in academic research at the Wistar Institute, Philadelphia, and focused his research on basic and translational melanoma research that resulted in several high impact publications.

From there, he joined MSD in in 2017 to continue clinical development in the melanoma team. This work led to the first approval of pembrolizumab in an adjuvant setting. He is now leading the melanoma global clinical development team at MSD and during his tenure the team has initiated two Phase 3 studies in adjuvant melanoma (KV-010 and INT-001) that promise to bring further improvements to adjuvant melanoma therapy with the coformulation MK-7684A and the INT product V940 being co-developed with Moderna.